Kenvue Inc. (NYSE:KVUE) Shares Sold by Americana Partners LLC

Americana Partners LLC trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 4.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,533 shares of the company’s stock after selling 4,397 shares during the period. Americana Partners LLC’s holdings in Kenvue were worth $2,125,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. State Street Corp grew its stake in shares of Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after buying an additional 7,115,374 shares in the last quarter. Holocene Advisors LP grew its position in Kenvue by 75.5% during the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares during the period. M&G PLC increased its holdings in Kenvue by 538.0% in the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after buying an additional 3,660,730 shares in the last quarter. Finally, FMR LLC increased its holdings in Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after buying an additional 3,075,019 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Up 2.3 %

Shares of KVUE opened at $21.94 on Tuesday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The firm has a market capitalization of $42.07 billion, a P/E ratio of 41.40, a P/E/G ratio of 2.16 and a beta of 1.45. The firm has a 50-day moving average price of $21.30 and a 200 day moving average price of $22.12. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts forecast that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Citigroup dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group reduced their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, February 7th. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.